참고문헌
- Ashton KA, Proietto A, Otton G, et al (2009). Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer. Gynecol Oncol, 113, 109-14. https://doi.org/10.1016/j.ygyno.2008.12.036
- Bai L, Zhu WG (2006). p53: structure, function and therapeutic applications. J Cancer Mol, 2, 141-53.
- Balik G, Kagitci M, Ustuner I, et al (2013). Which endometrial pathologies need intraoperative frozen sections? Asian Pac J Cancer Prev, 14, 6121-5. https://doi.org/10.7314/APJCP.2013.14.10.6121
- Dobrzycka B, Terlikowski SJ, Mazurek A, et al (2010). Circulating free DNA, p53 antibody and mutations of KRAS gene in endometrial cancer. Int J Cancer, 127, 612-21. https://doi.org/10.1002/ijc.25077
- Francisco G, Menezes PR, Eluf-Neto J, Chammas R (2011). Arg72Pro TP53 polymorphism and cancer susceptibility: a comprehensive meta-analysis of 302 case-control studies. Int J Cancer, 129, 920-30. https://doi.org/10.1002/ijc.25710
- Garcia-Dios DA, Lambrechts D, Coenegrachts L, et al (2013). High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma. Gynecol Oncol, 128, 327-34. https://doi.org/10.1016/j.ygyno.2012.11.037
- Harris N, Brill E, Shohat O, et al (1986). Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol, 6, 4650-6.
- Hecht JL, Mutter GL (2006). Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol, 24, 4783-91. https://doi.org/10.1200/JCO.2006.06.7173
- Hernandez E, ObermairA, Hoskins PJ, Magrina JF, McLellan R (2010). Controversies in the management of endometrial cancer. Obstet Gynecol Int, 894587.
- Hu Z, Li X, Qu X, et al (2010). Intron 3 16 bp duplication polymorphism of TP53 contributes to cancer susceptibility: a meta-analysis. Carcinogenesis, 31, 643-7. https://doi.org/10.1093/carcin/bgq018
- Hui P, Kelly M, O'Malley DM, Tavassoli F, Schwartz PE (2005). Minimal uterine serous carcinoma: a clinicopathological study of 40 cases. Modern Pathology, 18, 75-82. https://doi.org/10.1038/modpathol.3800271
- Jiang DK, Yao L, Ren WH (2011). TP53 Arg72Pro polymorphism and endometrial cancer risk: a meta-analysis. Med Oncol, 28, 1129-35. https://doi.org/10.1007/s12032-010-9597-x
- Lee E J, Kim TJ, Kim DS (2010). p53 alteration independently predicts poor outcomes in patients with endometrial cancer: a clinicopathologic study of 131 cases and literature review. Gynecol Oncol, 116, 533-8. https://doi.org/10.1016/j.ygyno.2009.11.018
- Levine RL, Cargile CB, Blazes MS (1998). PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer research, 58, 3254-8.
- Matei MC, Negura L, Liliac L, Negura A, Azoicai D (2012). Validation of PCR-RFLP techniques for the evaluation of codon 72 of p53 and CYP1A1 gene's polymorphisms in relation with ovarian cancer in a Romanian population. Rom J Morphol Embryol, 53, 47-54.
- Niwa Y, Hirose K, Matsuo K, et al (2005). Association of p73 G4C14-to-A4T14 polymorphism at exon 2 and p53 Arg72Pro polymorphism with the risk of endometrial cancer in Japanese subjects. Cancer letters, 219, 183-90. https://doi.org/10.1016/j.canlet.2004.10.018
- Oda K, Stokoe D, Taketani Y, McCormick F (2005). High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res, 65, 10,669-73.
- Rowlands IJ, Lee C, Janda M, et al (2013). Predicting positive and negative impacts of cancer among long-term endometrial cancer survivors. Psycho-Oncology, 22, 1963-71. https://doi.org/10.1002/pon.3236
- Saghir FS, Rose IM, Dali AZ, et al (2010). Gene expression profiling and cancer-related pathways in type I endometrial carcinoma. Int J Gynecol Cancer, 20, 724-31. https://doi.org/10.1111/IGC.0b013e3181e1c14c
- Salvesen HB, Carter SL, Mannelqvist M, et al (2009). Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci USA, 106, 4834-9. https://doi.org/10.1073/pnas.0806514106
- Santin AD, Zhan F, Cane S, et al (2005). Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. Br J Cancer, 92, 1561-73. https://doi.org/10.1038/sj.bjc.6602480
- Ueda M, Terai Y, Kanda K, et al (2006). Germline polymorphism of p53 codon 72 in gynecological cancer. Gynecologic oncology, 100, 173-8. https://doi.org/10.1016/j.ygyno.2005.08.015
- Zubor P, Stanclova A, Kajo K, et al (2009). The p53 codon 72 exon 4 BstUI polymorphism and endometrial cancer in Caucasian women. Oncology, 76, 173-83. https://doi.org/10.1159/000201570
피인용 문헌
- No Evidence of Association of the Arg72Pro p53 Gene Polymorphism with Cancer Risk in the Saudi Population: a Meta-Analysis vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5663
- Accuracy of Sentinel Node in Detecting Lymph Node Metastasis in Primary Endometrial Carcinoma vol.16, pp.15, 2015, https://doi.org/10.7314/APJCP.2015.16.15.6691
- C-kit Mutations in Endometrial Cancer: Correlation with Tumor Histologic Type vol.16, pp.17, 2015, https://doi.org/10.7314/APJCP.2015.16.17.7449
- Effect of p53β on human gastric cancer cells treated with recombinant mutated human TNF and cisplatin vol.15, pp.6, 2017, https://doi.org/10.3892/mmr.2017.6436
- No association of TP53 codon 72 and intron 3 16-bp duplication polymorphisms with breast cancer risk in Chinese Han women: new evidence from a population-based case–control investigation vol.23, pp.1, 2018, https://doi.org/10.1186/s40001-018-0345-6